{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:09:05Z","timestamp":1788505745834,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":661,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.cmi.2021.12.021","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T20:33:08Z","timestamp":1642105988000},"page":"936-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Mortality and clinical cure rates for pneumonia: a systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments"],"prefix":"10.1016","volume":"28","author":[{"given":"Naveed","family":"Saleem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ryckaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Arthur Chandos","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishkantha","family":"Arulkumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.12.021_bib1","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.ajic.2007.05.011","article-title":"Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries","volume":"36","author":"Chawla","year":"2008","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2021.12.021_bib2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF01690545","article-title":"Incidence and risk factors of pneumonia acquired in intensive care units. Results from a multicenter prospective study on 996 patients. European Cooperative Group on Nosocomial Pneumonia","volume":"19","author":"Chevret","year":"1993","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5507\/bp.2016.014","article-title":"Epidemiology of hospital-acquired pneumonia: results of a Central European multicenter, prospective, observational study compared with data from the European region","volume":"160","author":"Herkel","year":"2016","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.cmi.2021.12.021_bib4","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the myth of \u201cstatic vs cidal\u201d: a systemic literature review","volume":"66","author":"Wald-Dickler","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1086\/425009","article-title":"The importance of bactericidal drugs: future directions in infectious disease","volume":"39","author":"Finberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fpubh.2014.00217","article-title":"Vancomycin revisited\u201360 years later","volume":"2","author":"Rubinstein","year":"2014","journal-title":"Front Publ Health"},{"key":"10.1016\/j.cmi.2021.12.021_bib7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003495-200059040-00007","volume":"59","author":"Clemett","year":"2000","journal-title":"Linezolid Drugs"},{"key":"10.1016\/j.cmi.2021.12.021_bib8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dku379","article-title":"Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis","volume":"70","author":"Nemeth","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2021.12.021_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2021.12.021_bib11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1378\/chest.10-1556","article-title":"Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials","volume":"139","author":"Walkey","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2021.12.021_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jac\/dkh048","article-title":"Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: a randomized, double-blind, multicentre study","volume":"53","author":"Cepeda","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cmi.2017.06.013","article-title":"Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV\/AIDS: a randomized controlled trial","volume":"24","author":"Figueiredo-Mello","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.12.021_bib14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam\u2013macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib15","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.clinthera.2017.07.007","article-title":"A\u00a0phase II randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin for the treatment of nosocomial pneumonia suspected or confirmed to be due to gram-positive pathogens","volume":"39","author":"Huang","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2021.12.021_bib16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A\u00a0randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-020-01198-4","article-title":"Comparison of ceftriaxone plus macrolide and ampicillin\/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial","volume":"20","author":"Hamao","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A\u00a0phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF01968024","article-title":"Comparative study of azithromycin and amoxicillin\/clavulanic acid in the treatment of lower respiratory tract infections","volume":"10","author":"Balmes","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.119.1.185","article-title":"Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults","volume":"119","author":"Petitpretz","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2021.12.021_bib23","first-page":"28","article-title":"Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience","volume":"20","author":"Dartois","year":"2008","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diagmicrobio.2008.09.001","article-title":"Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin","volume":"63","author":"Bergallo","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2466-9-44","article-title":"Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia","volume":"9","author":"Tanaseanu","year":"2009","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-12-159","article-title":"Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin","volume":"12","author":"Ramirez","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.medmal.2013.09.011","article-title":"The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia","volume":"43","author":"Chavanet","year":"2013","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.cmi.2021.12.021_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib29","first-page":"373","article-title":"Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group","volume":"19","author":"Daniel","year":"1991","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.cmi.2021.12.021_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0732-8893(92)90135-G","article-title":"A\u00a0randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice","volume":"15","author":"Tilyard","year":"1992","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/37.suppl_C.93","article-title":"Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study","volume":"37","author":"Gris","year":"1996","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/37.suppl_C.103","article-title":"A\u00a0randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections","volume":"37","author":"Zachariah","year":"1996","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/9.6.479","article-title":"A\u00a0comparison of cefuroxime and co-trimoxazole in severe respiratory tract infections","volume":"9","author":"Mehtar","year":"1982","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jac\/14.1.75","article-title":"Erythromycin compared with a combination of ampicillin plus flucloxacillin for the treatment of community acquired pneumonia in adults","volume":"14","author":"Shanson","year":"1984","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/BF01975846","article-title":"Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia","volume":"10","author":"Kinasewitz","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia","volume":"14","author":"Bohte","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib37","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1378\/chest.110.6.1499","article-title":"Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin","volume":"110","author":"\u00d6rtqvist","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2021.12.021_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF01700406","article-title":"Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia","volume":"16","author":"Genne","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/39.4.499","article-title":"Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group","volume":"39","author":"Norrby","year":"1997","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib40","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1378\/chest.116.4.974","article-title":"A\u00a0multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia","volume":"116","author":"Moola","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2021.12.021_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0149-2918(00)88271-5","article-title":"Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia","volume":"21","author":"Ramirez","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2021.12.021_bib42","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1128\/AAC.44.7.1796-1802.2000","article-title":"Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia","volume":"44","author":"Plouffe","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0149-2918(02)85148-7","article-title":"A\u00a0controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia","volume":"24","author":"Gotfried","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2021.12.021_bib45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/0036554021000026933","article-title":"Linezolid versus ceftriaxone\/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia","volume":"34","author":"Pedro","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib46","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Dennis","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib47","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0149-2918(02)85136-0","article-title":"A\u00a0prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia","volume":"24","author":"Sokol","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2021.12.021_bib48","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2021.12.021_bib49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1469-0691.2004.0906.x","article-title":"A\u00a0randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia","volume":"10","author":"Lode","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.12.021_bib50","first-page":"1276","article-title":"Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients","volume":"127","author":"Kadowaki","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2021.12.021_bib51","first-page":"636","article-title":"Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study","volume":"17","author":"Kuzman","year":"2005","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib52","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.49.10.4035-4041.2005","article-title":"Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults","volume":"49","author":"D'Ignazio","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib53","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijantimicag.2008.04.004","article-title":"Linezolid for the treatment of infections caused by gram-positive pathogens in China","volume":"32","author":"Lin","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2021.12.021_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2008.04.009","article-title":"Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia","volume":"61","author":"Tanaseanu","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib56","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1378\/chest.08-0011","article-title":"Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"134","author":"Wunderink","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2021.12.021_bib57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2710.2009.01073.x","article-title":"Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia","volume":"35","author":"Mokabberi","year":"2010","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cmi.2021.12.021_bib59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib60","first-page":"77","article-title":"Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875\/125 mg twice daily for 7 days","volume":"20","author":"Paris","year":"2008","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2021.01.032","article-title":"Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia","volume":"104","author":"Torres","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib62","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib63","first-page":"111","article-title":"Erythromycin compared with a combination of ampicillin and amoxycillin as initial therapy for adults with pneumonia including Legionnaires' disease","volume":"7","author":"Macfarlane","year":"1983","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2021.12.021_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003495-198700341-00015","article-title":"An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections","volume":"34","author":"Harazim","year":"1987","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2021.12.021_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01962179","article-title":"Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia","volume":"7","author":"Zeluff","year":"1988","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0732-8893(92)90133-E","article-title":"Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections","volume":"15","author":"Dautzenberg","year":"1992","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib67","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1378\/chest.104.5.1393","article-title":"Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections","volume":"104","author":"Neu","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2021.12.021_bib68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2165\/00019053-199304020-00006","article-title":"Roxithromycin versus cefaclor in lower respiratory tract infection","volume":"4","author":"Scott","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cmi.2021.12.021_bib69","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/BF02464954","article-title":"Roxithromycin 150 mg bid versus amoxycillin 500 mg\/clavulanic acid 125 mg tid for the treatment of lower respiratory tract infections in general practice","volume":"23","author":"Karalus","year":"1995","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2021.12.021_bib70","first-page":"357","article-title":"Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections","volume":"46","author":"MacFarlane","year":"1996","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.cmi.2021.12.021_bib71","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archinte.160.9.1294","article-title":"Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial","volume":"160","author":"Vergis","year":"2000","journal-title":"Arch Int Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib72","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/rmed.2001.1113","article-title":"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia","volume":"95","author":"Hoeffken","year":"2001","journal-title":"Resp Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib73","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2021.12.021_bib74","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/500139","article-title":"Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer","volume":"42","author":"Jaksic","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib75","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/AAC.00197-13","article-title":"Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia","volume":"57","author":"Oldach","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib76","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib77","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/381972","article-title":"Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections","volume":"38","author":"Pankey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.12.021_bib78","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1128\/AAC.05798-11","article-title":"Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by gram-negative bacteria: results from a randomized clinical study","volume":"56","author":"Spyridaki","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/CCM.0b013e31822f0d2e","article-title":"Bactericidal antibiotics temporarily increase inflammation and worsen acute kidney injury in experimental sepsis","volume":"40","author":"Peng","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2021.12.021_bib80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.16.1.13","article-title":"Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens","volume":"16","author":"Rahal","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.12.021_bib81","series-title":"Community-acquired bacterial pneumonia developing drugs for treatment guidance for industry","author":"Center for Drug Evaluation and Research","year":"2020"},{"key":"10.1016\/j.cmi.2021.12.021_bib82","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thx.2010.143982","article-title":"Microbial aetiology of community-acquired pneumonia and its relation to severity","volume":"66","author":"Cilloniz","year":"2011","journal-title":"Thorax"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21007291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21007291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:31:54Z","timestamp":1761118314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21007291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1198743X21007291"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.12.021","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality and clinical cure rates for pneumonia: a systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}